B cell malignancies
Conditions
Interventions
experimental group:CFR64 T + anti-CD20 monoclonal antibody
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18-70 years old (including 18 and 70 years old); 2. Estimated survival time > 12 weeks; 3. B-cell lymphoma was diagnosed by pathological and histological examination, and the patient had relapsed or failed after receiving chemotherapy regimens containing CD20 monoclonal antibody; the patient voluntarily chose to infuse CFR64T cells combined with CD20 monoclonal antibody as salvage therapy; 4. Have measurable or evaluable lesions; 5. The main tissues and organs of the patient are in good function: (1) Liver function: ALT/AST = 95%; (4) Cardiac function: left ventricular ejection fraction (LVEF) >= 40%. 6. The peripheral superficial vein blood flow of the patient is smooth, which can meet the needs of intravenous infusion; 7. The patient's ECOG score is <= 2; 8. Patients or their legal guardians voluntarily participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or women who have pregnancy plans within half a year; 2. Patients with active hepatitis B or C infection; 3. Patients with infectious diseases (such as HIV, active tuberculosis, etc.); 4. Patients who need anti infection treatment for systemic infection or local severe infection; 5. Patients with serious autoimmune diseases; 6. Patients with high allergic constitution or severe allergic history; 7. The patients with abnormal vital signs and unable to cooperate with the examination; 8. Patients with mental or psychological diseases who can not cooperate with treatment and efficacy evaluation; 9. The doctor thinks there are patients who cannot be included in the treatment for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall response rate;Progression-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactKailin Xu
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed